

Early Diagnosis of Pediatric Crohn's Disease - Pointing Problems and Suggestions

Maraci Rodrigues*

Department of Gastroenterology, University of Sao Paulo School of Medicine Hospital das Clinicas, Brazil

***Corresponding author:** Maraci Rodrigues, Pediatric Gastroenterology, Department of Gastroenterology, University of Sao Paulo School of Medicine Hospital das Clinicas, Av. Dr Eneas de Carvalho Aguiar 255, 05403-000 Sao Paulo, Brazil, Tel: 55-11- 55613410; Email: maraci.rodrigues@hc.fm.usp.br

Published Date: June 23, 2016

Inflammatory Bowel Disease (**IBD**) includes Crohn's Disease (**CD**) and Ulcerative Colitis (**UC**) and can be diagnosed in childhood and adolescence in 25% of cases [1]. Children that contract IBD before 10 years of age almost always present with extensive colitis that cannot be classified as either UC or CD, and remain Colitis Not Determined (**CND**) until several years later [2].

Data from the literature on the time of diagnosis vary considerably. A pediatric IBD study in Germany found that the average time for CD diagnosis was 5 months (2-10 months), for the UC was 3 months (1-6 months) and CND was 4 months (2-11 months) and the growth deficit was the most common sign in cases with late diagnosis [3]. Compared to this study, the time interval between the onset of symptoms and the diagnosis was 4 and 2 months in a recent French study (EPIMAD) [4], 5 and 4 months in Noroega [5], 10 and 6 months in Italy [6] respectively for DC and UC.

The European study group recently published the record of new diagnoses of pediatric IBD; EuroKids aged 0-18 years between the years 2004-2009. This study gathered in 2087 patients, of which 59% were diagnosed with CD, 32% with UC and 9% as CND. The mean age at diagnosis was 12.1 years (0.6-17,9 years), and 56% boys [7].

Pediatricians should become familiar not only with the typical but also atypical presentations of IBD because 22% of children present with growth failure, anemia, perianal disease, or other extra-intestinal manifestations of the predominant only initial feature. A detailed family history should be obtained because 20% of children with IBD have an affected relative [2].

This section will be discussed only the diagnosis of pediatric Crohn's disease.

GASTROINTESTINAL MANIFESTATIONS IN CHILDREN AND ADOLESCENTS WITH CD

The clinical manifestations of CD depend on the site affected bowel, if it is in the upper gastrointestinal tract, the small intestine or colon, in the latter case simulating the UC. The highlight of the clinical manifestations of CD is the presence of abdominal pain associated with warning signs such as fever, growth retardation, pubertal delay, weight loss, pallor and perianal involvement (fistulas, fissures and abscesses). Sometimes, the picture begins acutely with symptoms of inflammatory acute abdomen, mimicking acute appendicitis. Patients with CD exhibit ileal more insidious onset of disease. Throughout evolution, complications may occur as substenoses bowel loops manifested with symptoms of occlusion or entero-enteric, enterocutaneous, perianal fistulas or fistulas between bowel loops and adjacent organs such as the bladder and genital [1,2,8].

The growth deficit that precedes the diagnosis is the biggest difference in the child's presentation of CD when compared to adults. The delay of puberty and decreased final adult stature can occur when the disease occurs in adolescence and there is delay in the diagnosis of CD. Furthermore, persistence of the growth deficiency may be the only signal to the diagnosis and disease activity, not only in performance but during the course of disease [1.2].

To evaluate these aspects of pediatric CD, we prospectively selected 22 patients with mildly to moderately active CD, 29 patients with inactive CD and 35 controls, undergoing regular treatment at the Clinical Gastroenterology Outpatient Clinical of the University of Sao Paulo School of Medicine Hospital das Clinicas, Sao Paulo, Brazil. The mean values for lean body mass, Tanner stage, height-for-age Z score and BMI-for-age Z score were lower in the active group than CD in the CD inactivate and control groups ($p < 0.05$ for both). When compared individually, 2 (9.1%) of the patients with active CD and 1 (3.4%) of those with inactive CD had short stature (height-for-age Z score < -2). In addition, 7 (31.8%) of the patients with active CD and 3 (10.3%) of those with inactive CD were malnourished (BMI-for-age Z score < -2). It is of note that some (4.2%) of our CD patients had a BMI-for-age Z-score > 2 standard deviation with characterized them the overweight [9].

It is important to note that the very early onset of IBD (younger than 2 years of life), is characterized by severe progressive colitis that can start before three months of life with failure to thrive, extensive colonic inflammation, perianal involvement, arthritis, folliculitis usually not compromising the small bowel, imposing differential diagnosis with monogenetics disease [10,11,12,13]. Table 1 summarizes the main differences of the clinical picture between CD and UC.

Table1: Percentage of Clinical Presentation Inflammatory Bowel Disease in Children and Adolescents.

Presenting Symptom	Crohn disease (% of patients)	Ulcerative Colitis (% of patients)
General		
Weight loss	55-80	31-38
Fever	38	NA
Anorexia	2-25	6
Growth retardation	3-4	0
Lethargy	13-27	2-12
Gastrointestinal tract		
Abdominal pain	67-86	43-62
Diarrhea	30-78	74-98
Rectal bleeding	22-49	83-84
Nausea/vomiting	6	<1
Constipation	1	0
Perianal disease	6-15	0
Mouth ulcers	5-28	13

Abbreviations: NA: Not Applicable. Range is derived from data reported by Kugathasan et al [14], Griffiths [15] and Sawczenko and Sandhu [16].

EXTRA-INTESTINAL MANIFESTATIONS IN CHILDREN AND ADOLESCENTS WITH CD

Despite its name, IBD is not limited to the intestine and about 30% of patients develop a previous extra-gastrointestinal manifestation or during evolution of their disease [17].

The extra-intestinal manifestations of IBD can be divided into a few categories:

- Related colitis (skin, eyes, joints and mouth) that occur in parallel with disease activity
- Hepatobiliary
- Deceleration of growth
- Secondary complications of the disease (nephrolithiasis, obstructive uropathy, and gallstone pancreatitis)
- Other events, which do not meet any previous criteria (amyloidosis, cancer, vascular, hematologic, pulmonary, cardiac and neurological)

Table 2 summarizes the main extra-intestinal manifestations in IBD in children and adolescents.

Table 2: Prevalence of intestinal manifestations in children and adolescents with IBD.

Extra-intestinal manifestation	Prevalence in CD (% of patients)	Prevalence in UC (% of patients)
Pyoderma gangrenosum		CR*
Joints/arthritis	-----	3.8
Osteoporosis and osteopenia	8-41	24-25
Growth delay	81	28
Nephrolithiasis	CR	3.2
Autoimmune hepatitis	-----	1.3
Uveitis	-----	0.63
Amyloidosis		CR
Vascular damage	4.2	0.63
Pancreatitis	3.9	2.5
Anemia	69	40.5

*except where noted by CR (case report) CD total N in children ranges from 21 to 26 and UC total N ranges from 21 to 158.

Data from: Jose FA and Heyman MB [17].

DIFFERENTIAL DIAGNOSIS

The clinical presentation of mucous and bloody discharge diarrhea may cover several etiologies [1,2,8]:

- infectious Colitis (Salmonella, Shigella, Yersinia, Campylobacter, Aeromonas, Mycobacterium tuberculosis and Entamoeba histolytica)
- pseudomembranous colitis (Clostridium difficile)
- Hemolytic uremic syndrome (Escherichia coli O157: H7)
- Parasitic (amebiasis, strongyloidiasis)
- Viral (cytomegalovirus and herpes simplex)
- vasculitis (Henoch-Schönlein and Behcet’s disease)
- Familial Mediterranean Fever (autosomal recessive disease)
- Acquired Immunodeficiency Syndrome (**AIDS**)
- Primary Immunodeficiency

Table 3 summarizes the main symptoms and alarm signals to the primary immunodeficiency

Table 3: Alarm signs and symptoms for primary immunodeficiency.

Positive family history of primary immunodeficiency
Consanguineous parents or > 2 family members with early-onset IBD Infantile (< 2 years) IBD
Severe, therapy-refractory IBD, particularly with perianal/rectovaginal disease/abscesses
Recurrent infections in the absence of immunosuppressant drugs (particularly pulmonary disease and skin abscesses)
Neutropenia, thrombocytopenia, or abnormal immune status (Ig levels) in the absence of immunosuppressant drugs
Nail dystrophy and hair abnormalities (trichorrhexis nodosa)
Skin abnormalities (congenital eczema, albino)

IBD: Inflammatory Bowel Disease; **Ig:** Immunoglobulin.

Data from: Levine et al [1].

The children with rectal bleeding can present ulcerative proctitis, which must be differentiated from other causes, such as anal fissure, hemorrhoids, polyps, and depending on the intensity of the intestinal bleeding, Meckel's diverticulum [1,2,8].

In children with pain in the lower right quadrant should be excluded acute appendicitis possibilities, tuberculosis and lymphoma. In patients with abdominal abscess, the differential diagnosis includes appendix or perforated vasculitis and trauma. In adolescents, should remember the gynecologic causes.

Moreover, it is necessary to differentiate the CD from UC, not always possible task when one does not have definitive pathologic findings of each disease, staying for some time Colitis Denomination Not Determined (**CND**) in 15% of cases [18].

When recurrent abdominal pain is the main symptom in children, it should be considered the possibility of dealing with Functional Gastrointestinal Disease (**FGID**), especially if there are intestinal and extra-intestinal symptoms unspecific. Thus, the identification of critical features or "red flags" can help pediatricians recognize the patient with FGID abdominal pain or CD, avoiding tests unnecessary diagnoses in patients with FGID and on the other hand, to prevent the delay diagnosis of CD [19].

In the study by El-Chammas et al characteristics of abdominal pain patient FGID were distinct from abdominal pain in patients with CD: (1) greater stress reports and headache ($p < 0.001$), (2) higher prevalence of FGID in family (irritable bowel syndrome or constipation, $p < 0.05$) and (3) lower reporting hematochezia, weight loss, difficulty gaining weight and greater presence of vomiting ($p < 0.05$). However, waking up at night and joint pain did not differ between the two groups. In contrast, the presence of anemia, hematochezia and weight loss was more predictive of CD (sensitivity 94%) [19].

DIAGNOSTIC APPROACH OF CD IN CHILDREN AND ADOLESCENTS

Clinical Symptoms

The diagnosis of IBD consists of a few steps, starting from the initial clinical suspicion pediatrician, based on clinical symptoms and physical examination with the referral of suspected cases to the Pediatric Gastroenterologist [1,2].

Physical Exam

The previous history data of height and weight are essential for detecting deceleration of the growth rate and weight loss. Furthermore, it should be observed if there is the presence of delayed pubertal development by Tanner scale [20].

Examines the color of mucous membranes to detect pallor (anemia), clubbing of finger nails and watch glass (present in chronic disease). The oral examination may show aphthous ulcers, angular cheilitis and tongue with a reduction of the papillae (iron deficits, vitamin B12, folic acid, zinc, etc.). Skin changes should be recorded (vitiligo, erythema nodosum and pyoderma gangrenosum).

Examination of the abdomen may show the tense wall, painful, and the presence of mass (suggestive of ileocecal abscess or infiltration). The evaluation of the joints can find signs of low back pain, arthritis or sacroiliitis. The anal area should be inspected to detect fissure, fistulas and perianal abscesses are more common in DC [1,2].

Laboratory tests

Initially, they must be rejected major diseases that mimic IBD through exams:

- Feces: stool culture and testing for toxin A and B of *Clostridium difficile*, to the exclusion of other causes of colitis
- Test of the purified protein derivative of tuberculin (**PPD**, Purified Protein Derivative of tuberculin) to ward off tuberculosis
- General Immunological evaluation to rule out the presence of primary immunodeficiencies
- Serology for AIDS

After this initial step, ask to laboratory tests related to inflammation, such as erythrocyte sedimentation, C-Reactive Protein (**CRP**), platelet, acid alpha-1-glycoprotein; if the results are high, reinforcing the diagnosis of IBD. One should also ask Cell Blood Count (**CBC**), with attention to the presence of hypochromic anemia and leukocytosis; and iron dosing and protein electrophoresis for detection of iron deficiency and secondary loss or hypoalbuminemia did not absorbed by inflamed intestinal mucosa. Among the serum electrolytes, the most common is the hypokalemia against attributed to chronic diarrhea [1,2].

The patient will be referred to the pediatric gastroenterologist when persist the diagnosis of IBD or to speed diagnosis.

Some non-invasive laboratory tests can increase the CD detection probability, such as lactoferrin and calprotectin in the faeces [21].

According to the study-level meta-analysis, in high-prevalence circumstances, faecal calprotectin can be used as a noninvasive biomarker of pediatric IBD only with a small risk of missing cases, and it can help in selecting patients for endoscopic evaluation and has the high overall sensitivity and the specificity for diagnosing IBD [22]. Another application of this method was the differentiation between functional disease and IBD [23].

The use of serological markers in children with suspected IBD is a noninvasive test application attempts to shorten the diagnosis, differentiate the DC from RCU and correlates them to prognosis of the disease. Many antibodies against microbial components are found in CD, including the antibody against outer membrane porin-C Escherichia coli (anti-OmpC), against the sequence I2 associated Pseudomonas (anti-I2) and against bacterial CBir1 flagina (anti-CBir1). It was found the prevalence of 11% and 56% of anti-anti-OmpC and I2 respectively in children with DC, with differences according to age at diagnosis. Other markers are anti-glican antibodies, results from the interaction between immune cells and glycosylated cell wall components of fungi, yeast, and bacteria are found in DC: Mannobioside Anti-Carbohydrate Antibodies (**AMCA**), Anti-Laminaribiose Carbohydrate Antibodies (**FTAA**), Anti-Carbohydrate Antibodies Chitobioside (**ACCA**), antilaminarim carbohydrate antibodies (anti-L), and anti-chitin (anti-C) carbohydrates antibodies. Only 16.9% -30.5% of patients were positive for each of them in pediatric CD [24].

Anti-Glicoprotein 2 (**GP2**) IgG and IgA, constituting novel CD specific autoantibodies, appears to be associated with distinct disease phenotypes Identifying patients at a younger age, with ileocolonic location, and structuring behavior with perianal disease [25].

Dosages of liver enzymes, bilirubin and amylase are intended to detect liver and pancreatic involvement in IBD, the disease itself or secondary to the use of drugs to treat the disease.

Recent meta-analysis determined the accuracy of diagnosis symptoms, signs, noninvasive tests, and test combinations that can assist the clinician with diagnosis of IBD in symptomatic children. The conclusions were children in the symptoms are not accurate enough to identify low-risk patients in whom an endoscopy can be avoided. Assessment of Fecal Calprotectin (**FCAL**), C-Reactive Protein (**CRP**), and albumin findings are potentially of clinical value, given their ability to select children at low risk (negative FCAL test result) or high risk (positive CRP or albumin test result) is IBD [26].

One such promising test, the polymorphonuclear CD64 index capitalizes on inflammation-induced expression of Fcy receptor I (CD64 markers) on neutrophils and has a high sensitivity and specificity for CD in children [27].

Normal laboratory evaluation result does not exclude the diagnosis of IBD because approximately 10% to 20% of children with IBD will have standard laboratory results [28]. If it persists the suspected diagnosis of IBD, even with regular screening tests, should continue the investigation, requesting to upper and lower endoscopy with serial biopsies.

Endoscopy

Upper endoscopy and accompanied ileocolonoscopy serially biopsy of the different segments of the digestive tract are the tests considered the gold standard for the diagnosis of CD, and definitely excludes other viral, bacterial and fungal etiologies. Macroscopic characteristics of the luminal pediatric untreated DC are summarized in **Table 4**.

Histology

Early manifestations of pediatric IBD can be relatively nonspecific. Initial mucosal biopsies may not be conclusive, delaying the diagnosis until subsequent biopsies typical histologic features of IBD.

In contrast to the findings of IBD, acute self-limited colitis (CALA) does not show the architectural distortion of the crypt, basal lymphoplasmocytosis and Paneth cell metaplasia. The combination of three parameters - increase of plasma cells in the lamina propria, crypt distortion and atrophy - represents 94% sensitivity and 96% specificity to distinguish IBD from other non-specific colitis [18].

A recent study investigated potential of early histologic markers of pediatric IBD. Its authors concluded that the distortion of colonic crypts, gastritis and the average density of eosinophils in the rectosigmoid were increased significantly in the IBD group compared to the group functional abdominal pain. Immunohistochemistry staining for tumor necrosis factor- α and matrix metalloproteinase-9 was performed on the stomach and rectosigmoid areas did not reveal any significant differences between the groups of the initial endoscopic evaluation [29].

Microscopic characteristics of the luminal pediatric untreated DC are summarized in Table 4.

Table 4: Macroscopic and microscopic features of DC pediatric luminal untreated.

Typical macroscopic findings of CD	Typical microscopic findings of CD
Mucosal aphthous ulcers	Noncaseating granuloma (s)- must be remote from ruptured crypt
Linear or serpentine ulceration	Focal chronic inflammation, transmural inflammatory infiltrate, submucosal fibrosis
Cobblestoning	
Stenosis/structuring of bowel with prestenotic dilatation	Nonspecific microscopic findings of CD
Imaging ou surgical-bowel wall thickening with luminal narrowing	Granuloma adjacent to ruptured crypt
Perianal lesions- fistula(s),abscesses, anal stenosis, and canal ulcers, large and inflamed skin tags	Mild nonspecific inflammatory infiltrate in lamina propria
Skip lesions	Mucosal ulceration/erosion
Jejunal or ileal ulcers	Signs of chronicity (eg.crypt architectural changes, colonic Paneth cell metaplasia and goblet cell depletion)
Nonspecific macroscopic findings of CD: oedema,erythema,friability, granularity	
Exudate: loss of vascular pattern, isolated aphthous ulcers, perianal lesions- midline anal fissures, small ski tags	

CD: Crohn Disease. Modification of Levine A et al [1].

Radiology

The imaging method for the evaluation of the small intestine is very important to evaluate the extent of disease, assess the severity, differentiate the DC RCU, and identify complications such as fistulae, abscesses and intestinal strictures. The current trend is to replace the intestinal transit by Computed Tomography Enterography (**CTE**) or Magnetic Resonance Enterography (**MRE**). Both techniques provide a perfect image enterography of the lumen and wall structures adjacent to the intestine. MRE advantages are the superior contrast resolution and the lack of ionizing radiation, although it is possible to maintain the quality of the image by CTE through interactive image reconstruction [30]. Some pediatric MRE protocols are available radiological studies should include Magnetic Resonance Pelvic to evaluate cases accompanied by perianal abscesses and fistulas [31].

Further Investigation

The realization of Endoscopy Capsule is authorized by the Food and Drug Administration (**FDA**) in the US for children above 10 years, but there are reports of children younger than held this diagnostic method by introducing the capsule endoscopically. This test allows evaluation of the entire small bowel mucosa, and is useful in children with persistent high digestive symptoms and radiological assessment of seemingly normal small intestine. The Endoscope Capsule may not be performed in the presence of intestinal stenosis, as in these cases the capsule can be retained in place. To rule out this possibility, one can use prior to the examination, a composite of biodegradable material capsule, the same size as used for the examination. If it is excreted intact, the patency of the intestinal lumen will be confirmed, enabling the final completion of the capsule endoscope, on the other hand, if there is impaction of the capsule in a stenosed intestinal segment, it will disintegrate in 40 hours due to the action of intestinal fluid [1].

The exploratory laparoscopy may be useful in selected cases patients, for example, when there is possibility of intestinal tuberculosis [1,2].

THE CLASSIFICATION OF PARIS

The classification of Paris [32], recently updated, to characterize the patient with DC according to age at diagnosis, location of the disease, inflammation behavior. It should be applied in the initial staging and progression of the disease, and this detailed in Table 5. As an adaptation to pediatric practice, was added to the discriminatory phenotype characteristic it was subdivided according to whether the disease was diagnosed before or after the patient was 10 years old, the presence or absence of growth failure, also introduced subdivision of upper gastrointestinal disease into jejunal versus oesophago-gastro-duodenal disease. The demarcation of the disease territory should be guided by inflammation Observed at endoscopy or imaging and not by microscopic Involvement.

Table 5: Paris Classification for Crohn’s disease.

Age Diagnosis	
•	A1a: 0- aged <10 years
•	A1b: 10- <17 years
Location	
•	L1: 1/3 distal ileum ± limited to the cecum
•	L2: Colonic
•	L3: ileocolónica
•	L4A: TGI proximal to the high angle of Treitz
•	L4B: TGI high distal to Treitz angle and proximal to the distal third of the ileum
Behavior	
•	B1: not stenotic and non-penetrating
•	B2: stenotic
•	B3: Penetrating
•	B2B3: both penetrating and stenosing
•	p: perineal disease
Growth	
•	G0: no evidence of stunting
•	G1: with evidence of growth deficit

The phenotype pediatric CD Characterized by more widespread intestinal inflammation, often Involving the large and small bowel as well as the upper gastrointestinal tract (pan-enteric disease) [8].

CONCLUSION

The DC has become an increasingly diagnosed in children of all ages. This condition is of particular clinical picture in children compared with adults. Perform early diagnosis is crucial to avoid an additional impact on the nutritional status, growing and pubertal development. It also requires attention to the consequences of DC on the psychosocial aspect of children and adolescents, as is common in DC school break and social activities, especially in those patients with unstable or severe disease, requiring psychological intervention.

References

1. Levine A, Kozlitzko S, D Turner, Escher JC, Cucchiara S, et al. European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. ESPGHAN Port revised criteria for the diagnosis of inflammatory bowel disease in children and adolescents. *J.Pediatric Gastroenterol Nutr.* 2014; 58: 795-806.
2. Rosen MJ, Dhawan A, Saeed SA. Inflammatory Bowel Disease in Children and Adolescents. *JAMA Pediatr.* 2015; 169: 1053-1060.
3. Behrens R, S Buderus, Findeisen. The Hauer The Keller KM et al. Childhood Onset Inflammatory Bowel Disease: Predictors of Delayed Diagnosis from the CEDATA German-Language Pediatric Inflammatory Bowel Disease Registry. *J Pediatr.* 2011; 158: 467-73.
4. Auvin S, Molinie F, Gower-Rousseau C, F Brazier, Merle V, Grandbastien B, et al. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France. *J Pediatr Gastroenterol Nutr.* 2005; 41: 49-55.977-80.
5. Bentsen BS, Moum B, Ekbohm A. Incidence of inflammatory bowel disease in children in southeastern Norway: a prospective population-based study 1990-94. *Scand J Gastroenterol.* 2002; 37: 540-545.
6. Castro M, Papadatou B, Baldassare M, Balli F, Barabino A. Inflammatory bowel disease in children and adolescents in Italy: data from the pediatric national IBD register. *Inflamm Bowel Dis.* 2008; 14: 1246-1252.
7. Bie CL, Buderus S, Sandhu BK de Ridder L Pærregaard A Veres G et al. EuroKids Port IBD Working Group of ESPGHAN. Diagnostic workup of pediatric Patients with inflammatory bowel disease in Europe: results of a 5-year audit of the EuroKids registry. *J Pediatr Gastroenterol Nutr.* 2012; 54: 374-380.
8. Malmberg P, Hildebrand H. The emerging global epidemic of paediatric inflammatory bowel disease - causes and consequences. *J Intern Med.* 2016; 279: 241-258.
9. Costa CO, Carrilho FJ, Nunes VS, Sipahi AM, Rodrigues M. A snapshot of the nutritional status of Crohn's disease among adolescents in Brazil: a prospective cross-sectional study. *BMC Gastroenterol.* 2015; 15: 172.
10. Kotlarz D, Beier R, D Muruga, Diestelhorst J, Jensen, Boztug K et al. Loss of Interleukin-10 Signaling and Infantile Inflammatory Bowel Disease: Implications for Therapy and Diagnosis. *Gastroenterol.* 2012; 143: 347-355.
11. Shah N, Kammermeier J, Elawad M, Glocker EO. Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. *Curr Allergy Asthma Rep.* 2012; 12: 373-379.
12. Shima OJ, Hwanga S, Yanga HR, Moona JS, Changa JY, Koa JS et al. Interleukin-10 receptor mutations in children with neonatal onset Crohn's disease and intractable ulcerating enterocolitis. *European Journal of Gastroenterology & Hepatology.* 2011; 25: 1235-1240.
13. Muise AM, Snapper SB, Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease. *Gastroenterology.* 2012; 143: 285-288.
14. Kugathasan S, Judd RH, RG Hoffman et al. Wisconsin Pediatric Inflammatory Bowel Disease Alliance. Epidemiologic and Clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. *J Pediatr* 2003; 143: 525-531.
15. Griffiths AM1. Specificities of inflammatory bowel disease in childhood. *Best Pract Res Clin Gastroenterol.* 2004; 18: 509-523.
16. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. *Arch Dis Child.* 2003; 88: 995-1000.
17. Jose FA, Heyman MB. Extraintestinal manifestations of inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* 2008; 46: 124-133.
18. Bousvaros A Antoniolli DA, Colletti RB, Dubinsky MC, Glickman JN, Gold BD, et al. Differentiating ulcerative colitis from Crohn's disease in children and young adults: report of the working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. *J Pediatr Gastroenterol Nutr.* 2007; 44: 653-74.
19. El-Chammas K, Majeskie A, Simpson P, Sood M, Miranda A. Red flags in children with chronic abdominal pain and Crohn's disease-a single center experience. *J Pediatr.* 2013; 162: 783-787.
20. Tanner, J.M. Growth at adolescence. 2nd.ed. Oxford: Blackwell Scientific, 1962.
21. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. *J Pediatr Gastroenterol Nutr.* 2001; 33: 14-22.
22. Holtman GA, Lisman-van Leeuwen Y, Reitsma JB, Berger MY3. Noninvasive Tests for Inflammatory Bowel Disease: A Meta-analysis. *Pediatrics.* 2016; 137.

23. Carroccio T, Iacono L, M Cottone Di Press L, Cartabellotta F, F Cavataio et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. *Clin Chem*. 2003; 49: 861-867.
24. Kovács M, Müller KE, Papp M, Lakatos PL, Csöndes M1. New serological markers in pediatric patients with inflammatory bowel disease. *World J Gastroenterol*. 2014; 20: 4873-4882.
25. Bogdanos DP, Roggenbuck D, Reinhold D, Wex T, Pavlidis P. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease. *BMC Gastroenterol*. 2012; 12: 102.
26. Degraeuwe PL, Beld MP, Ashorn M, Canani RB, Day AS. Faecal calprotectin in suspected paediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*. 2015; 60: 339-346.
27. Minar P, Haberman Y, Jurickova I, Wen T, Rothenberg ME. Utility of neutrophil Fc γ 3 receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease. *Inflamm Bowel Dis*. 2014; 20: 1037-1048.
28. Mack DR, Langton C, J Markowitz et al. Pediatric Inflammatory Disease Collaborative Research Group. Laboratory values for children with newly diagnosed inflammatory bowel disease. *Pediatrics* 2007; 119: 1113-1119.
29. Bass JA, Friesen CA, Deacy AD, Neilan NA5. Investigation of potential early Histologic markers of pediatric inflammatory bowel disease. *BMC Gastroenterol*. 2015; 15: 129.
30. Sauer CG1. Radiation exposure in children with inflammatory bowel disease. *Curr Opin Pediatr*. 2012; 24: 621-626.
31. Hammer MR, Podberesky DJ, Dillman JR. Multidetector computed tomographic and magnetic resonance enterography in children: state of the art. *Radiol Clin North Am*. 2013; 51: 615-636.
32. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. *Inflamm Bowel Dis*. 2011; 17: 1314-1321.